|
Status |
Public on Dec 17, 2014 |
Title |
Melanoma_Parental_1 [methylation] |
Sample type |
genomic |
|
|
Source name |
lymph node
|
Organism |
Homo sapiens |
Characteristics |
specimen type: Melanoma Cell line clinical stage: III braf inhibitor resistance: control
|
Treatment protocol |
M14 and M219 was treated by increasing concentrations of BRAF inhibitor SB590885 (up to 1uM), and resistant cell lines were screened for to yeild M14R and M219R.
|
Growth protocol |
Cell lines were grown at 37C in a 5% CO2 humidified atmosphere, in RPMI 1640 (Life Technologies-Bethesda Research Laboratories) supplemented with 10% fetal bovine serum.
|
Extracted molecule |
genomic DNA |
Extraction protocol |
gDNA was extracted from cell lines via Qiagen DNeasy Kit according to standard instructions and from tissue after microdissection from 10 μm-thick paraffin-embedded archival tissue using Qiagen DNeasy Kit according to standard instructions
|
Label |
Cy5 and Cy3
|
Label protocol |
Standard Illumina Protocol, run at USC core services
|
|
|
Hybridization protocol |
Sodium bisulfite modification (SBM) was performed on 1µg of gDNA using Zymo EZ DNA methylation kit (Zymo Research). An aliquot of SBM-gDNA was analyzed by MethyLight-based quality control to test bisulfite completeness. After correction of SBM-gDNA amount, 200 ng of SBM-gDNA was whole-genome amplified and enzymatically fragmented. Finally, the gDNA was hybridized in Infinium Human Methylation 450K BeadChip.
|
Scan protocol |
The chips were scanned with Illumina iScan using manufacturer recommended settings.
|
Description |
Sample name: M14 Stage III Melanoma
|
Data processing |
Data was extracted using the R package methylumi on Bioconductor.
|
|
|
Submission date |
Mar 30, 2013 |
Last update date |
Dec 17, 2014 |
Contact name |
Dave S.B. Hoon |
E-mail(s) |
hoond@jwci.org
|
Organization name |
Saint John's Cancer Institute
|
Department |
Translational Molecular Medicine
|
Street address |
2200 Santa Monica Boulevard
|
City |
Santa Monica |
State/province |
CA |
ZIP/Postal code |
90403 |
Country |
USA |
|
|
Platform ID |
GPL13534 |
Series (2) |
GSE45647 |
Anti-BRAF mutation drug resistance enhances EGFR expression in melanomas [methylation profiling] |
GSE45649 |
Anti-BRAF mutation drug resistance enhances EGFR expression in melanomas |
|